Data published from a retrospective study of over 33,000 postmenopausal women showed that patients taking Actonel® (risedronate sodium) were approximately half as likely to sustain a hip fracture as those taking alendronate in the first year of treatment.
read more »
Source:http://www.medicalnewstoday.com DiscussBury
Medinews is an online community dedicated for promoting and discussing latest medical news, research articles and blogs. You can also find regular updates on health news for discussion by health professionals.